journal
MENU ▼
Read by QxMD icon Read
search

New England Journal of Medicine

journal
https://www.readbyqxmd.com/read/28075694/cutaneous-eruption-in-a-u-s-woman-with-locally-acquired-zika-virus-infection
#1
Lucy Chen, Farhaan Hafeez, Christine L Curry, George Elgart
No abstract text is available yet for this article.
January 11, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28058966/repealing-the-aca-without-a-replacement-the-risks-to-american-health-care
#2
Barack H Obama
Health care policy often shifts when the country’s leadership changes. That was true when I took office, and it will likely be true with President-elect Donald Trump. I am proud that my administration’s work, through the Affordable Care Act (ACA) and other policies, helped millions more Americans..
January 6, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28051917/economic-effects-of-medicaid-expansion-in-michigan
#3
John Z Ayanian, Gabriel M Ehrlich, Donald R Grimes, Helen Levy
Under the Affordable Care Act, 31 U.S. states have opted to expand Medicaid coverage to nonelderly adults with annual incomes up to 138% of the federal poverty level (approximately $16,400 for a single adult in 2016). The federal government currently pays the full cost of Medicaid expansion in..
January 4, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28051914/intimate-choices-public-threats-reproductive-and-lgbtq-rights-under-a-trump-administration
#4
Melissa Murray
In the weeks since the election of Donald Trump, many experts have begun assessing the likely implications of his administration in various realms, from immigration and education to financial institutions and international relations. My concerns are decidedly more quotidian, though no less..
January 4, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28029802/should-medicare-value-based-purchasing-take-social-risk-into-account
#5
Karen E Joynt, Nancy De Lew, Steven H Sheingold, Patrick H Conway, Kate Goodrich, Arnold M Epstein
The United States is rapidly moving to a health care delivery system in which value-based payment models are the predominant way of reimbursing clinicians for care. Since caring for patients with social risk factors may cost more and make it harder to achieve high performance on quality metrics,..
December 28, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/28002688/ocrelizumab-versus-placebo-in-primary-progressive-multiple-sclerosis
#6
Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Annette Sauter, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Hideki Garren, Nicole Mairon, Peter Chin, Jerry S Wolinsky
Background An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease. Methods In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 24 weeks for at least 120 weeks and until a prespecified number of confirmed disability progression events had occurred...
December 21, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/28002679/ocrelizumab-versus-interferon-beta-1a-in-relapsing-multiple-sclerosis
#7
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Jerry S Wolinsky, Douglas L Arnold, Gaelle Klingelschmitt, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Peter Chin, Nicole Mairon, Hideki Garren, Ludwig Kappos
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end point was the annualized relapse rate. Results The annualized relapse rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0...
December 21, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/28001486/b-cell-depletion-a-frontier-in-monoclonal-antibodies-for-multiple-sclerosis
#8
Peter A Calabresi
No abstract text is available yet for this article.
December 21, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27973993/-zombie-outbreak-caused-by-the-synthetic-cannabinoid-amb-fubinaca-in-new-york
#9
Axel J Adams, Samuel D Banister, Lisandro Irizarry, Jordan Trecki, Michael Schwartz, Roy Gerona
Background New psychoactive substances constitute a growing and dynamic class of abused drugs in the United States. On July 12, 2016, a synthetic cannabinoid caused mass intoxication of 33 persons in one New York City neighborhood, in an event described in the popular press as a "zombie" outbreak because of the appearance of the intoxicated persons. Methods We obtained and tested serum, whole blood, and urine samples from 8 patients among the 18 who were transported to local hospitals; we also tested a sample of the herbal "incense" product "AK-47 24 Karat Gold," which was implicated in the outbreak...
December 14, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27973986/population-health-a-bipartisan-agenda-for-the-incoming-administration-from-state-leaders
#10
Christopher F Koller, Thomas Alexander, Susan Birch
The common goal of health policy leaders at the level of state government in the United States is promoting the health and well-being of all populations to the greatest extent possible within fixed resource constraints. Our health is affected by our physical and social environments, our genes, our..
December 14, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27973984/medicare-payment-for-behavioral-health-integration
#11
Matthew J Press, Ryan Howe, Michael Schoenbaum, Sean Cavanaugh, Ann Marshall, Lindsey Baldwin, Patrick H Conway
Integrating behavioral health care with primary care is now widely considered an effective strategy for improving outcomes for the many millions of Americans with mental or behavioral health conditions. Uptake of behavioral health integration (BHI) has remained limited, however, largely because BHI..
December 14, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27959700/osimertinib-or-platinum-pemetrexed-in-egfr-t790m-positive-lung-cancer
#12
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen, Chee K Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A Papadimitrakopoulou
Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed...
December 6, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27959702/thromboprophylaxis-after-knee-arthroscopy-and-lower-leg-casting
#13
Raymond A van Adrichem, Banne Nemeth, Ale Algra, Saskia le Cessie, Frits R Rosendaal, Inger B Schipper, Rob G H H Nelissen, Suzanne C Cannegieter
Background The use of thromboprophylaxis to prevent clinically apparent venous thromboembolism after knee arthroscopy or casting of the lower leg is disputed. We compared the incidence of symptomatic venous thromboembolism after these procedures between patients who received anticoagulant therapy and those who received no anticoagulant therapy. Methods We conducted two parallel, pragmatic, multicenter, randomized, controlled, open-label trials with blinded outcome evaluation: the POT-KAST trial, which included patients undergoing knee arthroscopy, and the POT-CAST trial, which included patients treated with casting of the lower leg...
December 3, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27959701/crizanlizumab-for-the-prevention-of-pain-crises-in-sickle-cell-disease
#14
Kenneth I Ataga, Abdullah Kutlar, Julie Kanter, Darla Liles, Rodolfo Cancado, João Friedrisch, Troy H Guthrie, Jennifer Knight-Madden, Ofelia A Alvarez, Victor R Gordeuk, Sandra Gualandro, Marina P Colella, Wally R Smith, Scott A Rollins, Jonathan W Stocker, Russell P Rother
Background The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that are involved in the pathogenesis of vaso-occlusion and sickle cell-related pain crises. The safety and efficacy of crizanlizumab, an antibody against the adhesion molecule P-selectin, were evaluated in patients with sickle cell disease. Methods In this double-blind, randomized, placebo-controlled, phase 2 trial, we assigned patients to receive low-dose crizanlizumab (2.5 mg per kilogram of body weight), high-dose crizanlizumab (5...
December 3, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27959704/clarifying-stem-cell-therapy-s-benefits-and-risks
#15
Peter W Marks, Celia M Witten, Robert M Califf
The current excitement over the potential for stem-cell therapy to improve patient outcomes or even cure diseases is understandable. We at the Food and Drug Administration (FDA) share this excitement. However, to ensure that this emerging field fulfills its promise to patients, we must first..
November 30, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27959709/a-fully-magnetically-levitated-circulatory-pump-for-advanced-heart-failure
#16
Mandeep R Mehra, Yoshifumi Naka, Nir Uriel, Daniel J Goldstein, Joseph C Cleveland, Paolo C Colombo, Mary N Walsh, Carmelo A Milano, Chetan B Patel, Ulrich P Jorde, Francis D Pagani, Keith D Aaronson, David A Dean, Kelly McCants, Akinobu Itoh, Gregory A Ewald, Douglas Horstmanshof, James W Long, Christopher Salerno
Background Continuous-flow left ventricular assist systems increase the rate of survival among patients with advanced heart failure but are associated with the development of pump thrombosis. We investigated the effects of a new magnetically levitated centrifugal continuous-flow pump that was engineered to avert thrombosis. Methods We randomly assigned patients with advanced heart failure to receive either the new centrifugal continuous-flow pump or a commercially available axial continuous-flow pump. Patients could be enrolled irrespective of the intended goal of pump support (bridge to transplantation or destination therapy)...
November 16, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/28079348/mental-illness-and-the-criminal-justice-system
#17
LETTER
Katherine L Harding
No abstract text is available yet for this article.
12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28079344/hepatic-encephalopathy
#18
LETTER
Amritangsu Borkakoty, Pramod Kumar, Sunil Taneja
No abstract text is available yet for this article.
12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28079343/hepatic-encephalopathy
#19
LETTER
(no author information available yet)
No abstract text is available yet for this article.
12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28079342/graves-disease
#20
LETTER
Jean-Paul Viard, Jacques Gilquin
No abstract text is available yet for this article.
12, 2017: New England Journal of Medicine
journal
journal
20199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"